In vitro inhibition of mumps virus replication by favipiravir (T-705).
Anti-viral
Favipiravir
MMR
Mumps
Paramyxovirus
T-705
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
10
03
2020
revised:
21
05
2020
accepted:
04
06
2020
pubmed:
20
6
2020
medline:
17
7
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
During the last decade multiple mumps outbreaks have occurred in the U.S. despite high two dose MMR coverage with most cases detected among two dose MMR vaccine recipients. Waning immunity, the evolution of wild-type virus strains, and settings with intense exposure have contributed to the resurgence of mumps. Typically, mumps virus infections resolve without serious clinical sequelae; however, serious complications may occur among unvaccinated or severely immunocompromised individuals. Favipiravir (T-705) has been shown to have in vitro anti-viral activity against a broad range of positive and negative strand RNA viruses. Here, we demonstrate that T-705 inhibits the growth of wildtype and vaccine strains of mumps virus in vitro at low micro-molar concentrations (EC
Identifiants
pubmed: 32553844
pii: S0166-3542(20)30263-1
doi: 10.1016/j.antiviral.2020.104849
pii:
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Pyrazines
0
RNA, Viral
0
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104849Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.